Literature DB >> 6213190

Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment.

A Mangione, F D Boudinot, R M Schultz, W J Jusko.   

Abstract

The dose dependence of mezlocillin pharmacokinetics was examined in relation to renal function after intravenous doses of 1 and 5 g in 16 subjects with various degrees of renal impairment. Dose and time-average model-independent physiological parameters were calculated from plasma concentration and urinary excretion data. Lack of superimposition of plasma concentration profiles occurred between dosage levels with a twofold exaggeration of areas under the curve produced between doses of 1 and 5 g. Decreased plasma clearances at the higher dose were caused partly by nonlinear renal clearance, but more markedly by dose dependence in nonrenal clearances. At each dosage level, these parameters were examined in relation to creatinine clearances. Plasma and renal clearances exhibited a typical linear correlation with creatinine clearance for each dose level. However, nonrenal clearances demonstrated a linear relationship with creatinine clearance at the 1-g dose, but apparent saturation of this pathway produced lower and relatively constant nonrenal clearance values at the 5-g dose. Mezlocillin pharmacokinetics are thus influenced by both dose and renal function over the dosage range of 1 to 5 g. Saturation in renal clearance and probably in biliary clearance explains the unusual disposition characteristics of mezlocillin observed in this and previously reported studies.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6213190      PMCID: PMC181910          DOI: 10.1128/AAC.21.3.428

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  Kinetics of Michaelis-Menten absorption of amino-penicillins in rats.

Authors:  A Tsuji; E Nakashima; I Kagami; T Asano; R Nakashima; T Yamana
Journal:  J Pharm Pharmacol       Date:  1978-08       Impact factor: 3.765

3.  Inhibition of intestinal (Na+--K+)-ATPase in experimental uremia.

Authors:  H J Kramer; A Bäcker; F Krück
Journal:  Clin Chim Acta       Date:  1974-01-19       Impact factor: 3.786

4.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

5.  Evidence of active transport of benzyl-14C-penicillin from cerebrospinal fluid to blood.

Authors:  R L Dixon; E S Owens; D P Rall
Journal:  J Pharm Sci       Date:  1969-09       Impact factor: 3.534

6.  Azlocillin and mezlocillin, two new alpha-amino-substituted penicillins. A comparison of the in vitro activity with other penicillins.

Authors:  R Wise
Journal:  Arzneimittelforschung       Date:  1979

7.  Pharmacokinetics of mezlocillin in healthy volunteers.

Authors:  T Bergan
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

8.  Elimination kinetics of mezlocillin in normal and impaired renal function including the effects of dialysis.

Authors:  J Kosmidis; P Doundoulaki; C Stathakis; N Zerefos; A Bounia; G K Daikos
Journal:  Arzneimittelforschung       Date:  1979

9.  Mezlocillin pharmacokinetics in patients with normal and impaired renal functions.

Authors:  T Bergan; E K Brodwall; E Wiik-Larsen
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

10.  Mezlocillin in the therapy of serious infections.

Authors:  S J Pancoast; J A Jahre; H C Neu
Journal:  Am J Med       Date:  1979-11       Impact factor: 4.965

  10 in total
  9 in total

1.  Application of moment analysis to nonlinear drug disposition described by the Michaelis-Menten equation.

Authors:  A T Chow; W J Jusko
Journal:  Pharm Res       Date:  1987-02       Impact factor: 4.200

2.  Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function.

Authors:  G L Jungbluth; D L Cooper; G D Doyle; G M Chudzik; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

4.  Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Authors:  Cornelia B Landersdorfer; Jurgen B Bulitta; Carl M J Kirkpatrick; Martina Kinzig; Ulrike Holzgrabe; George L Drusano; Ulrich Stephan; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

Review 5.  Penicillins. A current review of their clinical pharmacology and therapeutic use.

Authors:  Dilip Nathwani; Martin J Wood
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

6.  Comparative pharmacokinetics of two multiple-dose mezlocillin regimens in normal volunteers.

Authors:  P A Colaizzi; A A Coniglio; W J Poynor; N Vishniavsky; H T Karnes; R E Polk
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

7.  Dose-dependent pharmacokinetics of mezlocillin in rats.

Authors:  G L Jungbluth; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

8.  Effect of saturable clearance during high-dose mezlocillin therapy.

Authors:  G L Drusano; A Forrest; D Fiore; F Auger; E S Caplan
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

9.  Pharmacokinetics of two multiple-dose mezlocillin regimens.

Authors:  D M Janicke; S W Parker; R F Cafarell; M A Apicella; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.